ERBB2 and breast cancer: The aim of the NCT00312208 study was to compare the disease-free survival of patients with operable breast cancer with positive axillary lymph nodes who were HER2-neu negative and treated either with docetaxel combined with doxorubicin and cyclophosphamide (TAC) or with doxorubicin and cyclophosphamide, followed by docetaxel (AC-T) [102].